VELA Investment Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 39.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 8,386 shares of the company’s stock after purchasing an additional 2,355 shares during the period. VELA Investment Management LLC’s holdings in Johnson & Johnson were worth $1,300,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in Johnson & Johnson by 0.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after purchasing an additional 6,836 shares during the last quarter. Vaughan Nelson Investment Management L.P. lifted its stake in Johnson & Johnson by 21.8% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after purchasing an additional 161,687 shares during the last quarter. Scotia Capital Inc. lifted its stake in Johnson & Johnson by 1.6% in the 4th quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock valued at $195,247,000 after purchasing an additional 17,440 shares during the last quarter. Wisconsin Capital Management LLC lifted its stake in Johnson & Johnson by 0.8% in the 1st quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after purchasing an additional 127 shares during the last quarter. Finally, Boyar Asset Management Inc. lifted its position in Johnson & Johnson by 1.1% during the first quarter. Boyar Asset Management Inc. now owns 19,191 shares of the company’s stock worth $2,975,000 after acquiring an additional 201 shares during the last quarter. 67.57% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
JNJ has been the subject of several research reports. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Morgan Stanley restated an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a research report on Friday, July 21st. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Citigroup began coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price on the stock. Finally, Raymond James raised their target price on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a report on Monday, July 24th. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $171.80.
Johnson & Johnson Stock Performance
Shares of NYSE:JNJ opened at $173.46 on Tuesday. The company’s 50 day simple moving average is $165.20 and its 200 day simple moving average is $161.17. The stock has a market capitalization of $450.82 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 2.92 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the firm posted $2.59 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.75 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.74%. Johnson & Johnson’s payout ratio is presently 96.36%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is currently owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Best Stocks Under $10.00
- 3 Sizzling Dividends That Are Going On Sale
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Ways To Trade, Trade Desk Stock Post Earnings
- How to Invest in the Healthcare Sector
- Inflation, The Fed, and Oil Prices: Interest Rates Are Going Up
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
